“What If” I was seen, heard, and treated like a partner? Regarded as the greatest English novelist during the Victorian Era, Charles Dickens once said, “It was the best of times, it was the worst of times, it was the age of wisdom, it was the age of foolishness.” Those words never rang truer than…
ASTP is working with stakeholders to develop the next generation of FHIR capabilities such as a standard approach to enable writing health information from external sources into the patient health record
Perhaps this is what President Trump is exploring. Reuters reports: Drugmakers have been warned that the Trump Administration is considering linking U.S. medicine prices to lower amounts paid by other developed countries, according to two company sources who called the option the pharmaceutical industry’s top concern.Both sources, who were not authorized to speak publicly, said…
Fact sheet examining actions taken by the Trump administration and their impact on global health security and pandemic preparedness.
Platform being co-developed by Commure and HCA Healthcare is designed to support critical workflows in emergency departments, hospitalist operations, and ambulatory care
This issue brief describes states’ ongoing efforts to respond to shortages of home care workers and how they pay these workers, finding that increased payment rates are a key component of states’ efforts to address workforce shortages.
The real issue isn’t one payer, one policy or one bad actor. It’s a deeply fragmented system built on competing incentives, misaligned responsibilities and layers of administrative friction. The post Caught in the Middle: Unraveling Payer-Provider Blame in United States Healthcare appeared first on MedCity News.
Many people don’t understand why pharmaceuticals cost so much money. Don’t pharmaceutical companies make a lot of money? The answer is ‘yes’, but only if the drugs are successful. A paper by Wouters et al. (2024) found that: Based on data for 361 of 558 new therapeutic agents approved over the study period (median follow-up…
Eli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug candidates from previous deals with QurAlis and Verge Genomics. The post Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect appeared first on MedCity News.
The evolving landscape of healthcare demands that health plans continuously refine their engagement strategies, making this decision more critical than ever. Plan leaders must consider key factors, including cost, speed, scalability, and effectiveness, to guide them toward the most impactful approach. The post Navigating the Build vs. Buy Debate for Member Engagement Solutions appeared first…